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Background: It is well known that atrial ﬁbrillation (AF) and chronic kidney disease (CKD) are associated with a
higher risk of stroke, and new evidence links AF to cognitive impairment, independently from an overt stroke
(CI). Our aim was to investigate, assuming an underlying role of atrial microembolism, the impact of CI and
CKD in elderly hospitalized patients with AF.
Methods:Weretrospectively analyzed the data collected on elderly patients in 66 Italian hospitals, in the frame of
the REPOSI project. We analyzed the clinical characteristics of patients with AF and different degrees of CI. Mul-
tivariate logistic analysis was used to explore the relationship between variables and mortality.
Results: Among the 1384 patients enrolled, 321 had AF. Patients with AF were older, had worse CI and disability
and higher rates of stroke, hypertension, heart failure, and CKD, and less than 50%were on anticoagulant therapy.
Among patients with AF, those with worse CI and those with lower estimated glomerular ﬁltration rate (eGFR)
had a higher mortality risk (odds ratio 1.13, p = 0.006). Higher disability levels, older age, higher systolic
blood pressure, and higher eGFRwere related to lower probability of oral anticoagulant prescription. Lowermor-
tality rates were found in patients on oral anticoagulant therapy.
Conclusions: Elderly hospitalized patients with AF aremore likely affected by CI and CKD, two conditions that ex-
pose them to a highermortality risk. Oral anticoagulant therapy, still underused and not optimally enforced, may
afford protection from thromboembolic episodes that probably concur to the high mortality.© 2015 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.1. Introduction
Atrial ﬁbrillation (AF) is the most common cardiac rhythm disorder
[1]. It is expected to affect at least 5.6 million people in the US by the
year 2050. The burden of cognitive impairment (CI) and dementia is
also rising, as population ages and risk factors for CI increase [2].ey disease; CI, cognitive impair-
lant; SBT, Short Blessed Test; BI,
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cine. Published by Elsevier B.V. All rigA growing body of research links AF with a higher risk for CI and de-
mentia [3,4]. Patients with AF are known to have a four to ﬁve-fold
higher risk of stroke [5]; however, whether this is associated with CI
and dementia, and if so, how, is not fully understood. A recent review
found a signiﬁcant association between AF and dementia after a stroke
[6]. Other evidence, and in particular a systematic review of the litera-
ture, suggests that AF may favor cognitive decline before and indepen-
dently from an overt stroke [7,8]. Patients with persistent AF have
been found to have smaller total brain and gray matter volume, more
areas of silent cerebral ischemia and worse visual–spatial abilities than
patients with paroxysmal AF [9–11]. These ﬁndings suggest a possible
cumulative effect of AF on brain functions that worsens with time
from ﬁrst diagnosis.
On the other hand, it is well known that chronic kidney disease
(CKD) patients are at higher risk for ischemic stroke/cardiogenic cere-
bral embolism, with the risk increasing parallel to the fall in estimatedhts reserved.
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predictor of stroke among patients with non-valvular AF [15,16]. Fur-
thermore, CKD alone is associated with CI [17] and with brain lesions,
including silent cerebral ischemia and brain atrophy, predictive of
stroke, CI, and dementia, similar to ﬁndings reported in patients with
AF [10,18].
Taken together this evidence suggests that microemboli may con-
tribute to dementia in AF, and that the rate of atrial microthrombus for-
mation may be higher in CKD.
Recently, for stroke prevention in patients with AF, new oral antico-
agulants (NOACs) have been approved, and new guidelines have been
published [19,20]. While the European Society of Cardiology (ESC)
2012 guidelines did not recommend the use of NOACs in patients with
creatinine clearance (CrCl) b30 mL/min, [20] the new American Heart
Association/American College of Cardiology/Heart Rhythm Society
(AHA/ACC/HRS) 2014 guidelines approved the use of rivaroxaban at a
reduced dose in individuals with severe renal impairment (CrCl be-
tween 15 and 50 mL/min). Prescribing information indicates the use
of apixaban and rivaroxaban at a reduced dose in patients with
CrCl ≥ 15 mL/min, while dabigatran is not recommended when CrCl is
less than 30 mL/min [21–23]. These facts imply some limitations for
stroke prevention in patients with AF and CKD [19].
Given this background, the aim of our study was to examine the as-
sociation between AF and CI, and the relationship with CKD, in a cohort
of elderly patients hospitalized in internalmedicine and geriatric wards,
participating to the prospective REPOSI registry study.
2. Methods
2.1. Data collection and study population
We retrospectively analyzed the data collected in the frame of the
REPOSI project from January 2010 to December 2010 in 66 Italian hos-
pitals. REPOSI is an independent and collaborative registry, organized
by the Italian Society of Internal Medicine (SIMI) and the Mario Negri
Institute for Pharmacological Research. It involved the creation of a net-
work of internal medicine and geriatric wards that collected informa-
tion on elderly hospitalized patients, affected by multiple diseases and
on polytherapy, in a registry. The design of the project has been previ-
ously described in detail [24]. All patients with and without AF who
were recruited for the REPOSI study during the year 2010were included
in the present study analysis.
All patients provided informed consent. Data were collected in full
compliance with the Italian law on personal data protection, and the
REPOSI studywas approved by the Ethics Committee of each participat-
ing center.
2.2. Socio-demographic and clinical characteristics
We compared laboratory-clinical characteristics and socio-
demographic variables of patients with AF with those without AF.
The following clinical characteristics were evaluated: disease distri-
bution at hospital admission (the classiﬁcation was based on the Inter-
national Classiﬁcation of Diseases-Ninth Revision); cognitive status and
mood disorders (tested with the Short Blessed Test [SBT] [25] and the
Geriatric Depression Scale [26]); functional status at hospital admission
(measured bymeans of the Barthel index [BI] [27]) classiﬁed asmild (BI
75–90), moderate (BI 50–74), severe (BI 25–49), and total dependence
(BI 0–24); severity and comorbidity indexes (evaluated by the Cumula-
tive Illness Rating Scale [28]); kidney function by means of eGFR
(calculated using the Chronic Kidney Disease Epidemiology Collabora-
tion formula [29]); oral anticoagulant therapy; length of hospital stay;
destination at hospital discharge; and in-hospital and 3-month mortal-
ity rate. The associations between variables and mortality (in-hospital
and at 3-month follow-up) were analyzed.2.3. Cognitive status and anticoagulant therapy
We subdivided patients with AF according to cognitive status: with-
out CI (SBT score 0–4), moderate CI (SBT score 5–9), and severe CI (SBT
score 10–28). In these subsets of the population, we analyzed the avail-
able information on socio-demographic and clinical characteristics;
length of hospital stay; in-hospital and3-monthmortality rates; and an-
tithrombotic therapy at admission, discharge, and at 3-month follow-
up. Vitamin K antagonists (VKAs) were considered as oral anticoagu-
lants (OACs), and aspirin, clopidogrel, ticlopidine, and other anti-
aggregating agents were considered as antiplatelet drugs. According to
the Anatomical Therapeutic Chemical classiﬁcation, these drug types
were coded in the treatment database section as B01AA and B01AC, re-
spectively. Variables that could be related to lower prescription rates
were analyzed: age, male sex, eGFR, cirrhosis, systolic blood pressure,
BI, and stroke. 11 patients with AF were not included in these analyses,
since data on their SBT score was not available.
2.4. Statistical analysis
Data are reported as percentages for categorical variables and as
means (95% conﬁdence intervals) for quantitative variables. Analyses
were referred to the whole group, and gender categorization was ap-
plied. A BI score of≤40 was used to select patients with signiﬁcant dis-
ability according to our population characteristics. The comparison
between groups was made using Fisher's exact test for contingency ta-
bles and the z test for comparison of proportions. The non-parametric
Mann–Whitney U test was used for comparison of quantitative
variables. Multivariate logistic analysis was used to explore the relation-
ship between variables and outcomes (in-hospital and 3-month follow-
upmortality). Odds ratios and95% conﬁdence intervalswere computed.
The variables were chosen according to the Hosmer–Lemeshow
methodology [30]: after univariate analysis, only variables with a
p b 0.20 were included in the ﬁnal model; then, through a backward
process, variables were excluded until a signiﬁcance level of p b 0.20
was reached for each variable. A two-tailed p b 0.05was considered sta-
tistically signiﬁcant.
Stata Statistical Software 2011, Release 12 (StataCorp, College Sta-
tion, TX, USA) was used for database management and analysis.
3. Results
During the 4 index weeks, out of 1384 patients enrolled, 321 had AF
(47% male and 53% female). Among those with AF 45.2% had one or
more previous hospital admission and 58.2% had a caregiver. Patients
with AF were older (80.8 vs 78.5 years, p b 0.0001), had higher rates
of previous hospital admissions (one previous admission 30.2% vs
24.3%; more than one previous admission 15% vs. 12.2%; p = 0.011),
and were admitted to the hospital from the Emergency Departments
more frequently (85.3% vs 78.2%, p ≤ 0.005) than patients without AF.
No statistically signiﬁcant differences were found in sex, marital status,
and living arrangement at hospital admission between patients with
and without AF.
3.1. Clinical characteristics of patients with AF
At hospital admission, patientswith AF had higher heart rates, lower
eGFR values, higher hemoglobin levels, higher body mass index (BMI),
worse CI (higher SBT scores) and disability, and higher Illness Severity
and Comorbidity indexes than those without AF (Table 1). 280 patients
had permanent AF, while 41 had an episode of paroxysmal AF. Patients
with AFwere takingmoremedications, and a higher percentage of them
was on OAC therapy. Nevertheless, the percentage of patients with AF
taking OACs was less than 50%.
At hospital admission, the most frequent diagnoses in patients with
AFwere hypertension (84.4%), heart failure (37.1%), chronic obstructive
Table 1
Clinical characteristics of the REPOSI population with and without AF at hospital admission.
Patients with AF Patients without AF p
Number of patients 321 1063
Systolic blood pressure (mm Hg)a 132.4 (126.9–137.9) 133.1 (130.3–136.0) 0.933
Diastolic blood pressure (mm Hg)a 75.2 (72.3–78) 74.5 (73.1–76.0) 0.7170
Heart rate (bpm)a 88.5 (83.9–93.0) 78.8 (76.9–80.6) 0.002
Fasting glucose (mmol/L)a 6.79 (6.20–7.38) 6.94 (6.36–7.53) 0.3630
Creatinine (μmol/L)a 123.76 (97.24–152.06) 111.38 (102.54–120.22) 0.0672
eGFRa 53.3 (48.4–58.1) 59.6 (56.6–62.6) 0.0133
Hemoglobin (g/L)a 121 (116–126) 116 (113–119) 0.0205
Cholesterol (mmol/L)a 4.18 (3.91–4.45) 4.15 (3.99–4.30) 0.2442
Body mass index (kg/m2)a 26.7 (26.1–27.3) 25.9 (25.5–26.2) 0.0103
Waist circumference (cm)a 94.4 (92.6–96.2) 93.4 (92.4–94.4) 0.3691
Visceral obesity (%) 47.8 45.1 0.447
Cognitive impairment (SBT score)a 13.0 (11.1–14.9) 10.2 (9.2–11.2) 0.0189
Cognitive impairment (SBT score ≥10) (%) 52.7 46.1 0.044
Barthel index (disability)a 66.3 (59.0–73.6) 75 (71.0–78.9) 0.0041
Geriatric Depression Scalea 1.46 (1.17–1.75) 1.32 (1.15–1.49) 0.7433
Number of drugs at hospital admissiona 6.2 (5.9–6.4) 5.2 (5.1–5.4) b0.0001
Number of drugs at hospital dischargea 7.1 (6.8–7.4) 6.2 (6.0–6.4) b0.0001
Number of drugs at follow-upa 6.8 (6.5–7.2) 6.0 (5.8–6.3) 0.0004
Severity index (CIRS)a 1.74 (1.67–1.80) 1.66 (1.62–1.69) b0.0001
Comorbidity index (CIRS)a 3.38 (3.03–3.74) 3.04 (2.82–3.27) b0.0002
Subjects taking OACs at hospital admission (%) 44.5 4.3 b0.001
Subjects taking OACs at hospital discharge (%) 48.7 5.1 b0.001
Subjects taking OACs at follow-up (%) 51.0 6.9 b0.001
AF, atrial ﬁbrillation; CIRS, Cumulative Illness Rating Scale; eGFR, estimated glomerular ﬁltration rate; OAC, oral anticoagulant; SBT, Short Blessed Test.
a Data are reported as means (95% conﬁdence interval).
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(27.4%), diabetes mellitus (27.4%), coronary artery disease (26.8%), ma-
lignancy (20.9%), hypertensive heart disease (15.9%), valvular disease
(10.9%), and stroke (8.4%). Patients with AF had higher rates of stroke
(8.4% vs 3.8%, p = 0.02), hypertension (84.4% vs 77%, p = 0.005),
heart failure (37.1% vs 17.4%, p b 0.001), and CKD (27.4% vs 19.8%,
p = 0.005), but lower rates of malignancy (20.9% vs 31.4%, p b 0.001).
In patients with paroxysmal AF, the stroke rate was higher (14%).
The mean length of hospital stay of patients with AF was 10.9 days
(95% conﬁdence interval = 9.97–11.8). The in-hospital mortality rate
was 4.7%, and during 3 months after discharge, it reached 7.3%. At dis-
charge, 86.5% of patients with AF went home, 3% needed home care,
and 7% were institutionalized. In addition, 3.5% of patients with AF
were re-admitted to the hospital within 3 months. Patients with AFTable 2
Mortality and socio-demographic/clinical characteristics in AF patients with and without CI.
Patients without CI (SBT score 0–4) Patients with
Number of subjects 90 56
Agea 77.8 (76.3–79.3) 80.4 (78.8–82
Men (%) 43.9 57.1
Women (%) 56.1 42.9
Systolic blood pressure (mm Hg)a 134.1 (129.1–139.2) 125.4 (120.9–
Diastolic blood pressure (mm Hg)a 77.0 (74.1–79.8) 74.5 (71.2–77
Heart rate (bpm)a 81.6 (77.7–85.4) 86.6 (81.1–92
eGFRa 62.8 (58.1–67.4) 52.9 (47.4–58
Hemoglobin (g/L)a 125 (119–129) 125 (119–131
BMIa (kg/m2) 26.5 (25.4–27.6) 26.3 (25.1–27
Visceral obesity (%) 38.7 46.0
Barthel index ≤40 (disability) (%) 4.4 7.1
Geriatric Depression Scalea 1.15 (0.94–1.37) 1.39 (1.08–1.
Comorbidity index (CIRS) ≥3 61.5 62.5
Length of hospital staya (days) 9.3 (7.9–10.7) 11.9 (9.4–14.
In-hospital mortality (%) 1.1 1.8
3-month mortality (%) 1.6 10.2
AF, atrial ﬁbrillation; BMI, body mass index; CI, cognitive impairment; CIRS, Cumulative Illness
a Data are reported as means (95% conﬁdence interval).were more likely to be institutionalized (7% vs 2.6%, p = 0.0070) at dis-
charge than those without AF.
3.2. Cognitive impairment, kidney function, and mortality
Patients with severe CI (SBT score N 10)were older, had a higher de-
gree of disability, a higher rate of in-hospital mortality, and lower eGFR
than thosewith a normal SBT score (Table 2).When comparing patients
with AF and normal cognitive function to those with an abnormal
SBT (SBT score: 5–28), the latter group had higher mortality rates at
the 3-month follow-up (1.6% vs 9.7%, p = 0.0423). Among patients
with AF, a worse CI (higher SBT score) was, in fact, associated with a
higher risk of in-hospital mortality (Fig. 1). On the other hand, patients
with higher eGFR were at lower risk of in-hospital death. This effect ofmoderate CI (SBT score 5–9) Patients with severe CI (SBT score 10–28) p
164
.0) 82.8 (81.7–83.8) 0.001
55 0.155
45
129.9) 134.1 (130.2–138) 0.890
.8) 75.1 (72.9–77.3) 0.4057
.1) 86.6 (83.4–89.9) 0.1440
.5) 54.6 (51.0–58.2) 0.0108
) 120 (117–123) 0.2806
.5) 26.9 (26.0–27.8) 0.6816
52.4 0.144
28.7 b0.001
71) 1.34 (1.14–1.54) 0.4041
66.5 0.708
5) 11.5 (1.01–12.9) 0.049
7.9 0.028
9.5 0.102
Rating Scale; eGFR, estimated glomerular ﬁltration rate; SBT, Short Blessed Test.
Fig. 1.Multivariate analysis of the association between clinical and demographic variables and in-hospital mortality in patients with atrial ﬁbrillation. BMI, body mass index; C.I., conﬁ-
dence interval; eGFR, estimated glomerular ﬁltration rate.
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(Fig. 2),while higher SBT scores andmalignancy increased themortality
risk.
3.3. Oral anticoagulant therapy
Regarding anticoagulant or antiplatelet therapy prescription, the
rate of OAC use was less than 60%, independent of the degree of CI
(Table 3). When analyzing possible modiﬁers of antithrombotic pre-
scription at admission, higher disability level (BI ≤ 40), higher systolic
blood pressure, and higher eGFRwere the only variables found to be re-
lated to lower prescription probability. At discharge, older age was also
found to be related to a lower prescription probability (Table 4). Cirrho-
sis and stroke, other variables taken into considerationwhen evaluating
bleeding risk in the HAS-BLED score [31], were also associated withMalignancy
Short Blessed Test (SBT) score
BMI
Barthel index  40
eGFR 
Age 
Male gender
Variable
4.29 (1.07-17.15)
1.13  (1.04-1.24)
0.79 (0.66-0.95)
0.72 (0.13-4.06)
0.97  (0.94-1.00)
1.15 (1.00-1.31)
1.77 (0.45-6.93)
Odds ratio (95% C.I.)
0.040
0.006
0.011
0.706
0.038
0.048
0.414
P
≤
Fig. 2.Multivariate analysis of the association between clinical and demographic variables and 3
interval; eGFR, estimated glomerular ﬁltration rate.lower prescription rates; however, these associations were not statisti-
cally signiﬁcant.
Patients with AF taking OACs had lower, but not statistically signiﬁ-
cant, mortality rates both in-hospital (2.8% vs 6.3%, p = 0.189) and at
the 3-month follow-up (4% vs 10.5%, p = 0.108) than those not taking
OACs.
4. Discussion
The aim of the present study was to assess the possibility that atrial
microembolism can contribute to CI and CKD in untreated patients with
AF, and that OAC can afford a signiﬁcant protection against this risk.
We found that elderly hospitalized patients with AF are more fre-
quently affected by CI and CKD than are other elderly hospitalized pa-
tients and that CI, together with CKD, can herald short-term mortality0.1 1 10 100
O dds ratio
-monthmortality in patients with atrial ﬁbrillation. BMI, bodymass index; C.I., conﬁdence
Table 3
Antithrombotic therapy prescription rates in patients with AF and CI.
Patients
without CI
(SBT score 0–4)
Patients with
moderate CI
(SBT score 5–9)
Patients with
severe CI
(SBT score 10–28)
p
Oral anticoagulant therapy (%)
Hospital admission 48.9 51.8 41.0 0.272
Hospital discharge 51.8 58.0 44.3 0.212
3-month follow up 51.7 57.1 48.5 0.665
Antiplatelet drugs (%)
Hospital admission 23.3 26.5 32.3 0.372
Hospital discharge 30.1 32.0 32.1 0.907
3-month follow up 34.5 31.4 29.7 0.665
AF, atrial ﬁbrillation; CI, cognitive impairment; SBT, Short Blessed Test.
247S. Corrao et al. / European Journal of Internal Medicine 26 (2015) 243–249risk. Higher SBT scores predicted a higher in-hospital and 3-monthmor-
tality risk. Our results in AF patients conﬁrm the ﬁndings of a recent
study on elderly Taipei citizenswith CI [32]. Researchers have formulat-
ed different explanations for the higher mortality in patients with CI: CI
may interferewith treatment compliance [33]; cognitive deﬁcitsmay be
amarker of a general decline in health [34]; and CImay reﬂect a speciﬁc
disease progression. In patientswith AF, this latter hypothesisﬁnds sup-
port in the pathogenetic links that have been formulated between AF
and CI: shared risk factors (hypertension, diabetes, and congestive
heart failure) [35]; beat-to-beat variability and reduced cardiac output,
that may alter cerebral blood perfusion [9]; and hypercoagulable state,
that may lead to the formation of thrombi in the left atrial appendage
and ultimately to clinical and subclinical strokes [36].
In this regard, micro-infarcts, caused by microemboli originating in
the heart, have been suspected to be a cause of brain atrophy and of le-
sions widely distributed on both sides of the brain [9,37] and therefore,
eventually, of CI.
Regarding renal function, we found that, in elderly hospitalized pa-
tients with AF, higher eGFRs are related with a lower mortality risk.
This implies that patients with worse renal function are at higher risk.
Furthermore, we found that worse kidney function was also related to
worse CI. It may as well be that patients with AF release microemboli
in the circulation, hitting preferentially the brain (CI) and the kidney
(more severe CKD), where the circulation is of terminal type.
Additionally, we observed a lower mortality risk, at the 3-month
follow-up, in patients with higher BMI. This is probably due to the
high mortality risk in underweight elderly patients [38].
Regarding anticoagulant therapy, less than 60% of the patients with
AF in our study were on OAC therapy. Moreover, among patients with
severe CI, less than 50% were on OAC therapy. In our analysis, OACs
were less likely to be prescribed to patients with higher eGFR than
those with lower eGFR. However, the odds ratio was 0.98 and theTable 4
Multivariate analysis of the association between clinical and demographic variables and
anticoagulant prescription in patients with atrial ﬁbrillation.
Odds ratio (95% conﬁdence interval) p
Prescription at admission
Age 0.97 (0.93–1.02) 0.201
Male sex 1.83 (1.07–3.14) 0.027
eGFR 0.98 (0.97–1.00) 0.006
Cirrhosis 0.33 (0.07–1.57) 0.165
Systolic blood pressure 0.09 (0.04–0.18) b0.001
Barthel index ≤40 0.28 (0.13–0.61) 0.001
Prescription at discharge
Age 0.94 (0.89–0.98) 0.007
eGFR 0.98 (0.97–1.00) 0.019
Cirrhosis 0.39 (0.07–2.04) 0.264
Stroke 0.48 (0.16–1.50) 0.209
Systolic blood pressure 0.09 (0.05–0.18) b0.001
Barthel index ≤40 0.26 (0.11–0.62) 0.002
eGFR, estimated glomerular ﬁltration rate.conﬁdence interval close to 1; hence, this has little clinical relevance.
Nonetheless, one of the possible explanations could be that the reduc-
tion in kidney function was perceived by the physician as a variable
which may determine the indication for an increased thromboembolic
risk. On the other hand, the overall underuse of anticoagulants that
we recorded may be very dangerous. In patients with CKD, this is very
important since, among patients with non-valvular AF, patients with
renal failure not on OAC therapy have a four-fold greater risk of mortal-
ity than those with normal renal function [12].
On the other hand, sub-optimal control of OAC therapy (Internation-
al Normalized Ratio [INR] values not within the therapeutic range) in
patients with AF has also been linked to CI [39,40]. In elderly patients,
the management of VKA can be particularly challenging [41]. In these
patients there is great variability in dose requirements and, when INR
values are too high, it takes longer to return to therapeutic ranges
[42]. Thismay also be due to difﬁculties in following complicated dosing
schedules and attending the regular INR monitoring. This situation may
worsen when patients are affected by CI. In our study, physicians were,
in fact, less likely to prescribe anticoagulant drugs to patients with
worse disability levels and older age. All this can become even more
complex in elderly patients with CKD. These patients experience a de-
crease in anticoagulant stability when taking VKA, and need more fre-
quent monitoring and twice as frequent dose adjustments compared
with patients that have normal renal function [43].
NOACs may help address these problems that physicians encounter
with elderly patients. In particular, for patients with AF and CKD, NOACs
are now available and have been tested. Rivaroxaban has shown to
have a consistent anticoagulant effect and safety in the elderly and in
patients with lower GFR [41,44]. In the ROCKET-AF trial, given the avail-
able pharmacokinetic data on rivaroxaban in patients with deep vein
thrombosis [45], researchers established the safety and efﬁcacy of the
drug at a reduced dose (15 mg once daily) in patients with an eGFR of
30–49 mL/min [46,47]. In the Re-LY trial, dabigatran has been analyzed
in patients with a CrCl higher than 30 mL/min, in two different dosages
(110 mg or 150 mg twice daily), but without a speciﬁc dosage for
kidney impairment [48]. In the ARISTOTLE trial, the use of a reduced
dose of apixaban (2.5 mg twice daily) was investigated in patients
with two of the following criteria: age ≥80 years, weight ≤60 kg,
and serum creatinine ≥ 133 μmol/L (1.5 mg/dL) [49]. Rivaroxaban
(15 mg once daily), in particular, on the grounds of these trials, has
been included in the 2014 AHA/ACC/HRS guidelines as an option for an-
ticoagulant therapy in patients with non-valvular AF and CKDwith CrCl
≥15 mL/min. Dabigatran (75 mg twice daily), based on modeling stud-
ies, has also been included for patients with severe renal impairment,
but this indication has not been validated in a prospective cohort, and
the prescribing information on in the European Summary of Product
Characteristics (SmPC) still does not include this indication [21].
While according to the European SmPC, apixaban is indicated in pa-
tients with CrCl ≥ 15 mL/min at a reduced dose, it has not been recom-
mended for patients with severe kidney impairment by the ESC or the
AHA/ACC/HRS guidelines [19,22]. Hopefully, further studies will help
determine whether these NOACs can address effectively the issue of
undertreatment in elderly patients with AF and CKD and whether
they can help prevent cognitive decline and mortality by reducing the
ischemic lesions.
4.1. Strengths and limitations
The major strength of the present study is the multicenter design of
the REPOSI registry and the inclusion of patients in index weeks,
3 months apart from each other, which enabled balancing the effect of
the seasons on diseases. Regarding the limitations, because of the limit-
ed sample size, it was not possible to analyze the incidence of stroke in
patients with AF according to the degree of CI. The sample size also lim-
ited the possible analysis on INR values and on GFR and anticoagulant
prescription. Speciﬁc analysis evaluating variables such as the individual
248 S. Corrao et al. / European Journal of Internal Medicine 26 (2015) 243–249stages of CKD may be useful in understanding which patients are
at higher risk of anticoagulant underuse. Finally, since thiswas an obser-
vational study and not a clinical trial, the reported associations between
CI, CKD, and mortality cannot be interpreted as indicative of a causal
role.
Learning points
• Elderly hospitalized patients with atrial ﬁbrillation have worse cogni-
tive impairment and kidney function compared to patients without
atrial ﬁbrillation.
• Worse impairment in cognitive and kidney function is associatedwith
a higher short-term mortality risk in elderly hospitalized patients
with atrial ﬁbrillation.
• Oral anticoagulation is inadequately implemented in this population,
especially in patients with higher disability levels and those of older
age.
• Since ischemic lesions, due tomicroemboli, may link atrial ﬁbrillation,
chronic kidney disease and cognitive impairment, higher prescription
rates and adherence to anticoagulant therapy may help prevent cog-
nitive decline and lower mortality.
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